Glanbia

Glanbia, an Irish company operating in the Pharmaceutical Preparation Manufacturing industry, has reported its carbon emissions for recent years. In 2025, the company's total emissions, encompassing Scope 1, 2, and 3, were approximately 9,800,071,000 kg CO2e. This figure comprises Scope 1 emissions of approximately 150,088,000 kg CO2e, Scope 2 emissions (market-based) of approximately 47,296,000 kg CO2e, and Scope 3 emissions totalling approximately 9,600,403,000 kg CO2e.

For the year 2024, Glanbia's total emissions were approximately 10,799,624,000 kg CO2e. This breaks down into Scope 1 emissions of approximately 143,479,000 kg CO2e and Scope 2 emissions (market-based) of approximately 69,497,000 kg CO2e, with Scope 3 emissions at approximately 10,588,253,000 kg CO2e.

In 2023, Glanbia reported total emissions of approximately 11,576,259,000 kg CO2e, with Scope 1 at approximately 144,041,000 kg CO2e and Scope 2 at approximately 86,074,000 kg CO2e, and Scope 3 at approximately 11,288,218,000 kg CO2e.

Glanbia has established several significant climate commitments. The company aims for a 50% absolute reduction in its operational emissions (Scope 1 and 2) by 2030, using 2018 as the baseline year. Furthermore, Glanbia has committed to reducing its Scope 3 GHG emissions from purchased goods and services by 25% per tonne of dairy product produced by 2030, also from a 2018 baseline. The Science Based Targets initiative (SBTi) has validated these targets, noting that the Scope 1 and 2 targets are consistent with limiting warming to 1.5°C. Additionally, Glanbia has a long-term ambition to achieve net-zero emissions by 2050, covering emissions across its entire value chain, including upstream and downstream activities.